Giovanni Luca Ceresoli
Humanitas Gavazzeni · 364 works · 10,201 citations · h-index 50
Top works
- Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
- A Randomized Study of Lung Cancer Screening with Spiral Computed Tomography
- Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer
- IncreasedHER2Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor–Positive Non–Small-Cell Lung Cancer Patients
- Gefitinib in Pretreated Non–Small-Cell Lung Cancer (NSCLC): Analysis of Efficacy and Correlation With HER2 and Epidermal Growth Factor Receptor Expression in Locally Advanced or Metastatic NSCLC
- Primary cardiac lymphoma in immunocompetent patients
- Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial
- Phase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma
- Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study
- Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment
- Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6–70.2 Gy)
- Early Response Evaluation in Malignant Pleural Mesothelioma by Positron Emission Tomography With [18F]Fluorodeoxyglucose
- Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
- Primary pulmonary meningioma
- Differential diagnosis and management of focal ground-glass opacities
- Adding Gemcitabine to Paclitaxel/Carboplatin Combination Increases Survival in Advanced Non–Small-Cell Lung Cancer: Results of a Phase II-III Study
- Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma
- Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis
- HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients
- Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey